Merrill maintains Qiagen at sell

Qiagen NV was maintained by Merrill Lynch analyst Erica Whittaker at a sell rating. Merrill increased its net sales and gross profits forecasts by 2% to 3%. But, these upgrades are offset by higher operating expenses, resulting in minimal changes to earnings per share. Better-than-anticipated operating margin leverage may enable the company to meet or beat the analyst's bottom line forecasts during 2006. Shares of the Venlo, The Netherlands, pharmaceutical company were up 6 cents, or 0.46%, at $13.24 on volume of 497,492 shares versus the three-month running average of 278,449 shares. (Nasdaq: QGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.